医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe

2016年03月16日 PM11:00
このエントリーをはてなブックマークに追加


 

EL PASO, Texas

Premier Biomedical, Inc. (OTCQB: BIEI) announced that they have engaged the services of an agent affiliated with the Chinese pharmaceutical industry to seek out suitable joint venture partners in China and Europe. The agent will act in Premier’s interests in locating and securing financing and suitable joint venture partners in China and Europe for the purposes of testing, registering and marketing medications and devices being developed by Premier for the treatment of various diseases, such as fibromyalgia, MS, and cancer.

William A. Hartman, President and CEO of Premier Biomedical, stated, “We believe there are significant advantages in seeking a joint venture with Chinese and European biomedical/pharmaceutical partners, and see this as the next step to expanding our potential market coverage. This effort does not lessen the importance of securing similar JV arrangements in Brazil, India, and the rest of Asia, but, in fact, complements those efforts.”

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/

Safe Harbor Notice

Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160316005713/en/

CONTACT

Premier Biomedical, Inc.
William A. Hartman, 724-633-7033
President
and CEO
PR@premierbiomedical.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究